Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $30.27

Posted by Geri Gentry on Jun 9th, 2026

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $30.2727.

A number of brokerages have recently issued reports on BCAX. Morgan Stanley lifted their price target on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. The Goldman Sachs Group lifted their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Bank of America began coverage on Bicara Therapeutics in a research note on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, March 31st.

Read Our Latest Stock Report on BCAX

Bicara Therapeutics Trading Up 0.5%

Shares of BCAX opened at $20.10 on Thursday. Bicara Therapeutics has a 12 month low of $8.48 and a 12 month high of $24.25. The stock’s 50 day moving average is $21.58 and its two-hundred day moving average is $18.82. The firm has a market cap of $1.32 billion, a P/E ratio of -7.23 and a beta of -0.54.

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Equities research analysts forecast that Bicara Therapeutics will post -3.48 EPS for the current year.

Insider Transactions at Bicara Therapeutics

In other news, insider David Raben sold 5,500 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $22.88, for a total value of $125,840.00. Following the sale, the insider directly owned 55,286 shares of the company’s stock, valued at $1,264,943.68. The trade was a 9.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 12,500 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $20.29, for a total value of $253,625.00. Following the transaction, the chief operating officer directly owned 191,641 shares in the company, valued at $3,888,395.89. This trade represents a 6.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 100,600 shares of company stock valued at $2,119,199. Insiders own 13.80% of the company’s stock.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCAX. Legal & General Group Plc boosted its stake in Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after buying an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Bicara Therapeutics during the fourth quarter worth $45,000. Larson Financial Group LLC boosted its stake in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after buying an additional 3,595 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares during the last quarter.

Bicara Therapeutics Company Profile

(Get Free Report)

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.